Updated on 19 March 2013
GC-Rise attracts investors at China conference
Singapore: GC-Rise Pharmaceutical attracted the attention of investors at the annual China Healthcare Investment Conference in Shanghai. Beijing-headquartered GC-Rise, which focuses on women's and children's health in China, took the opportunity to showcase its growth stories and seek tie-ups with partners from the most promising public and private Chinese healthcare companies.
On top of the new moves, the pediatrics pharmaceutical market has been incorporated into GC-Rise's specialties, reshaping the company's five strategic focuses into anti-aging products, respiratory diseases in children, pregnancy and new born health, skin care products, and mental health and child development.
Mr Wren Zhang, strategic director, GC-Rise, "The market size of GC-Rise's strategic focus in China's women's and children's health is expected to see compound annual growth rate of 28% over the period of 2010-2017 due to growing healthcare awareness. Technical advancements have helped the POCT market grow at a double digit CAGR from 2009-11, which is expected to reach $25 billion worldwide by 2016, while China will be one of the fastest growth drivers."
Furthermore, GC-Rise will foray into point-of-care testing (POCT) in the OB-GYN and pediatrics market taking advantages of the company's broad commercial channels and close connections with physicians. GC-Rise, founded in 2008, has seen rapid growth over five years of continuous expansion. The company has been listed in the top 50 fast-growing companies in China by Deloitte for two consecutive years in 2011 and 2012 as the only pharmaceutical enterprise.
The company also initiated the country's first GYN/OB Physician Award in China joining hands with China Physician Association in 2012. China Health Care Investment Conference is organized by a group of investors including KPCB, Fidelity Asia Ventures, Vivo Ventures and Piper Jaffray. The group is committed to turn this meeting into a powerful platform to promote and nurture the Chinese healthcare investment ecosystem and further develop the industry.